Nanoparticles inspired by lung fluid improve therapies targeting respiratory system

AI justification

Breakthrough medical innovation with high therapeutic potential and no identified ethical harms. | The development of targeted nanoparticle therapies for pulmonary fibrosis represents a significant advancement in medical treatment, directly improving health outcomes (SDG 3) while reducing side effects. The innovation aligns with ethical principles of beneficence and non-maleficence, with no identified negative ethical aspects in this action.